Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease

PharmaSources.comFebruary 01, 2021

Tag: Mallinckrodt , CELLEX® , Chronic Graft Versus Host Disease

PharmaSources Customer Service